ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response

Sousa, LGD; Rajapakshe, K; Canales, JR; Chin, RL; Feng, L; Wang, Q; Barrese, TZ; Massarelli, E; William, W; Johnson, FM; Ferrarotto, R; Wistuba, I; Coarfa, C; Lee, J; Wang, J; Melief, CJM; Curran, MA; Glisson, BS

Curran, MA (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Dept Immunol, Houston, TX 77030 USA.;Curran, MA (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.;Curran, MA (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022; 10 (2):

Abstract

Background The combination of ISA101, a human papilloma virus (HPV) 16 peptide vaccine, and nivolumab showed a promising response rate of 33% in patie......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索